What you should know:
Hello Summer, a digital health Offering information on the lifecycle of medicines and quality medical practice from an exclusive real-world data network, announced today a $ 150 million round of E-Series funding led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) i New growth, the growing investment branch of Novo Holdings.
– Existing Verana Health investors Teacher (formerly Google Ventures), Casdin Capital, and Brook Byers also joined the round, as did notable new investors, including the Merck Global Health Innovation Fund, THVC, i Breyer Capital.
Empower physicians and life sciences companies
Founded in 2018, with this capital infusion, Verana Health is on the verge of accelerating its position as a market leader in providing real-world quality data to drive quality knowledge throughout the life cycle of medicines. The company will build on its strong technology and data ecosystem: the VeraQ ™ platform and its Qdata ™ care in ophthalmology, neurology and urology, to advance the enabling of clinical trials, software as a service and l real world evidence. The company will also expand its establishment artificial intelligence (AI) with a particular focus on its pioneering use of natural language processing (NLP) to extract information from unstructured text data in Electronic health record (EHR) notes.
In October 2021, Verana Health launched its VeraQ ™ population health data engine, which is led by the physician and enhanced by AI to safely feed a feedback loop of data integrity of almost half a million unidentified health encounters. The result is Qdata ™ selected: Disease-specific and purpose-specific data modules designed to help life sciences companies confidently drive business knowledge and rigorously report research results.
Verana Health is the exclusive data partner of the American Academy of Ophthalmology, the American Urological Association, and the American Academy of Neurology and collaborates with multinational pharmaceutical companies as well as emerging biotechnology and biopharmaceutical companies.
The funding will allow the company to advance its life science product and service strategy over the life cycle of the drug, further enhancing its value proposition for healthcare providers involved in its network. real-world data and expand its data footprint through medical society and strategic partnerships.
“The healthcare industry needs new ways to create high-quality datasets from disorganized information scattered across a myriad of electronic health record systems that often lack interoperability and standardization,” said David W. Parke II, MD , CEO and CEO of Verana Health. his first partner in the medical society, the American Academy of Ophthalmology. “Verana Health is addressing this critical need by delivering and analyzing proprietary and curated (Qdata) data sets, both structured and unstructured data that hold the truth in the original clinical context. The company is well positioned to help healthcare providers advance quality of care standards, and life sciences companies to accelerate clinical research and bring products to market that benefit both patients and physicians. “